AUG 19·SEC EDGARLow
Williams Amanda M purchased $16K of ACON
Williams Amanda M purchased 5,857 shares of Aclarion, Inc. (ACON) at $2.73 on 2026-08-17.
StockNASDAQ · US · USDHealthcare · Health Information Services
$ACON
Aclarion, Inc.
Price · $ACONvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $ACON in the last 7 days.
Insider · 30dAll trades →
- Buys
- $126K 6 txs
- Sells
- — 0 txs
Bond Ryan1× · $50K
10b5-1 share of filings0%
Top stories · $ACONMore →
AUG 18·SEC EDGAR
Gould Gregory A purchased $24K of ACON
Gould Gregory A (CFO) purchased 10,000 shares of Aclarion, Inc. (ACON) at $2.45 on 2026-08-14.
AUG 17·SEC EDGAR
Bond Ryan purchased $50K of ACON
Bond Ryan purchased 21,122 shares of Aclarion, Inc. (ACON) at $2.37 on 2026-08-13.
ACON sentiment & insider activity
Recent ACON coverage spans insider activity, technology and financial news.
In the last 30 days, ACON insiders filed 6 SEC Form 4 transactions — 6 purchases ($126K) and no sales. The most active reporter was Bond Ryan with 1 filing.
What's driving ACON
Small insider buy may signal confidence but limited market impact due to modest size.
This is an insider open-market buy by the CFO, which can be read as mild positive sentiment but is not a fundamental catalyst by itself.
This is a director open-market buy disclosed via Form 4, which can be mildly supportive for sentiment but is not a fundamental catalyst by itself.
The filing discloses a director adding shares via an open-market purchase, but the disclosed size is small and lacks guidance or operational catalysts.
The filing is a modest insider buy signal, but it is not a new operational or financial catalyst.
alphai scores every news story that mentions ACON with an AI model for sentiment and relevance, and aggregates insider trades from Aclarion, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ACON
Score
Williams Amanda M purchased $16K of ACON
Williams Amanda M purchased 5,857 shares of Aclarion, Inc. (ACON) at $2.73 on 2026-08-17.
1 min readGould Gregory A purchased $24K of ACON
Gould Gregory A (CFO) purchased 10,000 shares of Aclarion, Inc. (ACON) at $2.45 on 2026-08-14.
1 min readBond Ryan purchased $50K of ACON
Bond Ryan purchased 21,122 shares of Aclarion, Inc. (ACON) at $2.37 on 2026-08-13.
1 min readWesemann William purchased $5K of ACON
Wesemann William purchased 2,150 shares of Aclarion, Inc. (ACON) at $2.34 on 2026-08-13.
2 min readNeal David K purchased $18K of ACON
Neal David K purchased 7,500 shares of Aclarion, Inc. (ACON) at $2.40 on 2026-08-13.
2 min readNess Brent purchased $12K of ACON
Ness Brent (Chief Executive Officer) purchased 5,234 shares of Aclarion, Inc. (ACON) at $2.31 on 2026-08-13.
1 min readAclarion, Inc.: Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process
Aclarion, Inc. (Nasdaq: ACON) said the USPTO issued a Notice of Allowance for a patent application covering “Multi-Voxel Prescription for Lumbar Disc Evaluation,” aimed at improving MR spectroscopy voxel positioning in its Nociscan workflow. The company said the claims are intended to reduce repeat scans and variability across sites, extending its IP portfolio of 65+ patents worldwide.
3 min readAclarion, Inc.: Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026
Aclarion (Nasdaq: ACON) published a CEO shareholder letter updating progress in H1 2026. The company cited 141% YoY and 71% sequential scan volume growth, U.K. reimbursement momentum, a U.S. Market Access Program with PRIA Healthcare, and continued CLARITY trial site expansion. It reported $16.3M cash and no debt as of June 30, 2026.
4 min read
Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan’s Growing Role in Real
Aclarion (Nasdaq: ACON) said two abstracts on its Nociscan MR Spectroscopy platform were presented at the ASPN annual meeting. A real-world study workflow using Nociscan in 20 patients was described, and a case study reported 95% relief after basivertebral nerve ablation guided by Nociscan in a patient without classic Modic MRI changes.
3 min read
Aclarion Announces Texas Spine Care Center as New CLARITY Site
Aclarion (Nasdaq: ACON) said Texas Spine Care Center will join its 300-patient, prospective randomized CLARITY trial evaluating Nociscan for surgical treatment of discogenic chronic low back pain. The primary endpoint is 12-month change in VAS back pain. Aclarion expects an initial internal readout and early interim results disclosure in Q4 2026.
3 min read